Evolent Health announced that former CVS Caremark and WellBe Senior Medical CFO Mario Ramos will take the helm of the company’s finance function, effective immediately. The Compensation Committee approved a one‑time, time‑based restricted stock unit award for 587,500 shares of Class A common stock, with a grant‑date value of $2.35 million. The award vests in three tranches—34 % on the first anniversary, 33 % on the second, and 33 % on the third—subject to continued employment.
Ramos brings a decade of experience in large‑scale financial operations and integrations. He led the financial integration of Aetna into CVS and served as CFO of WellBe Senior Medical, where he managed multi‑million‑dollar budgets and drove cost‑control initiatives. His track record suggests Evolent is positioning itself for disciplined financial stewardship amid a period of strategic realignment.
Evolent’s recent results underscore the need for seasoned financial leadership. In Q3 2025 the company reported an earnings‑per‑share miss, while revenue edged up slightly, reflecting pressure in its largest Performance Suite segment. The firm also completed a divestiture of its value‑based primary‑care business and announced an oncology partnership, signaling a shift toward higher‑margin specialty services. These moves, coupled with the EPS miss, highlight the importance of a CFO who can navigate cost discipline and capitalize on new growth opportunities.
The restricted‑stock unit award was granted under NYSE Listing Rule 303A.08, a standard inducement for new executives who are not prior employees. By tying a substantial portion of compensation to long‑term equity, Evolent aligns Ramos’s interests with shareholders and incentivizes a sustained commitment to the company’s strategic goals.
The appointment signals Evolent’s intent to strengthen its financial discipline and accelerate execution on its strategic initiatives. With Ramos’s experience in large‑scale integrations and cost management, the company is better positioned to address revenue headwinds, optimize its capital structure, and support the expansion of its oncology and other specialty services. The award and leadership change together suggest a renewed focus on long‑term value creation for investors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.